With respect to RAB27B, metabolic reprogramming mediated by RAB27B was verified to induce doxorubicin resistance in breast cancer cells [71], and it was found that RAB27B is involved in chemoresistance to cisplatin in pancreatic cancer [72]. Here, RAB27B is linked to breast cancer.